Ausdal Financial Partners Inc. Has $654,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Ausdal Financial Partners Inc. raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 67.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,509 shares of the medical research company’s stock after purchasing an additional 1,008 shares during the quarter. Ausdal Financial Partners Inc.’s holdings in Amgen were worth $654,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Legacy Investment Solutions LLC acquired a new stake in Amgen in the third quarter valued at about $29,000. Centricity Wealth Management LLC acquired a new stake in shares of Amgen in the 4th quarter valued at approximately $25,000. Synergy Investment Management LLC bought a new stake in shares of Amgen during the 4th quarter valued at approximately $34,000. Atala Financial Inc acquired a new position in Amgen during the 4th quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC bought a new position in Amgen in the 4th quarter valued at approximately $36,000. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the transaction, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by corporate insiders.

Amgen Stock Performance

Shares of Amgen stock opened at $305.77 on Friday. The business has a 50-day simple moving average of $300.39 and a 200 day simple moving average of $298.51. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm has a market capitalization of $164.26 billion, a price-to-earnings ratio of 40.50, a PEG ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.11%. The ex-dividend date is Friday, May 16th. Amgen’s payout ratio is presently 126.09%.

Analyst Ratings Changes

Several research analysts have recently issued reports on AMGN shares. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Citigroup reaffirmed a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler lifted their price target on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Johnson Rice set a $294.00 price objective on Amgen in a research note on Wednesday, March 5th. Finally, UBS Group reiterated a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $314.04.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.